2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.
Ruth Aiwu He, MD, PhD, scientific lead in liver and biliary cancers at Georgetown-Lombardi Comprehensive Cancer Center, discusses the results of the LEGACY study in patients with hepatocellular carcinoma (HCC).
The LEGACY study was a retrospective analysis of patients with early-stage HCC who received Y-90 glass microspheres (TheraSphere), according to He. In the overall cohort, Y-90 demonstrated a best overall response rate of 88%, with a complete response rate of 83%, says He.
Additionally, the therapy resulted in prolonged disease control, and the 3-year overall survival rate in patients with transplant or resection following Y-90 was 93%, says He. Overall, the results of the study appear to be quite promising, He concludes.